Patents by Inventor Martin John Schnermann

Martin John Schnermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210198196
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Application
    Filed: February 18, 2021
    Publication date: July 1, 2021
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Publication number: 20210100919
    Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.
    Type: Application
    Filed: February 14, 2019
    Publication date: April 8, 2021
    Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Martin John SCHNERMANN, Peter C.W. KIM, Jaepyeong CHA, Roger Rauhauser NANI
  • Patent number: 10961193
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 30, 2021
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Publication number: 20210017132
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Application
    Filed: February 15, 2019
    Publication date: January 21, 2021
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • Publication number: 20210010914
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Patent number: 10874739
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 29, 2020
    Assignee: The Unites States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Patent number: 10876003
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: December 29, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Patent number: 10830678
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: November 10, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Publication number: 20200121790
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicant: The United States of America, as represented by the Secretary Department of Health and Human Service
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Patent number: 10561729
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 18, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka
  • Publication number: 20190225811
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Publication number: 20190167793
    Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.
    Type: Application
    Filed: August 7, 2017
    Publication date: June 6, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
  • Patent number: 10280307
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: May 7, 2019
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Publication number: 20180273758
    Abstract: Embodiments of C4?-alkyl-ether heptamethine cyanine fluorophores according to general formula I, and pharmaceutically acceptable salts thereof, are disclosed. Methods of making and using the C4?-alkyl-ether heptamethine cyanine fluorophores also are disclosed.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 27, 2018
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Martin John Schnermann, Roger Rauhauser Nani, James Blaine Shaum
  • Publication number: 20170122853
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Application
    Filed: August 7, 2015
    Publication date: May 4, 2017
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann